Conclusions Bleeding in ACS Coordination of care through cooperation between ED and IC Treatment (EDICT for ACS) is essential to navigate the new landscape Coordination of care through cooperation between ED and IC Treatment (EDICT for ACS) is essential to navigate the new landscape ACC/AHA guidelines now recognize the value of bleeding reduction in ACS care ACC/AHA guidelines now recognize the value of bleeding reduction in ACS care Bivalirudin is a Class I (Level of evidence: B) recommended antithrombin agent for NSTE ACS patients undergoing an invasive strategy Bivalirudin is a Class I (Level of evidence: B) recommended antithrombin agent for NSTE ACS patients undergoing an invasive strategy ACUITY demonstrates that bivalirudin provides protection from ischemic events while reducing bleeding risk ACUITY demonstrates that bivalirudin provides protection from ischemic events while reducing bleeding risk Coordination of care through cooperation between ED and IC Treatment (EDICT for ACS) is essential to navigate the new landscape Coordination of care through cooperation between ED and IC Treatment (EDICT for ACS) is essential to navigate the new landscape ACC/AHA guidelines now recognize the value of bleeding reduction in ACS care ACC/AHA guidelines now recognize the value of bleeding reduction in ACS care Bivalirudin is a Class I (Level of evidence: B) recommended antithrombin agent for NSTE ACS patients undergoing an invasive strategy Bivalirudin is a Class I (Level of evidence: B) recommended antithrombin agent for NSTE ACS patients undergoing an invasive strategy ACUITY demonstrates that bivalirudin provides protection from ischemic events while reducing bleeding risk ACUITY demonstrates that bivalirudin provides protection from ischemic events while reducing bleeding risk
{}